INCY 5 (Jakafi 5 mg)
Generic Name: ruxolitinib
Pill imprint INCY 5 has been identified as Jakafi 5 mg.
Jakafi is used in the treatment of myelofibrosis; polycythemia vera; myeloproliferative disorders and belongs to the drug class multikinase inhibitors. Risk cannot be ruled out during pregnancy. Jakafi 5 mg is not a controlled substance under the Controlled Substance Act (CSA).
- Generic Name:
- ruxolitinib
- Imprint:
- INCY 5
- Strength:
- 5 mg
- Color:
- White
- Shape:
- Round
- Availability:
- Prescription only
- Drug Class:
- Multikinase inhibitors
- Pregnancy Category:
- C - Risk cannot be ruled out
- CSA Schedule:
- Not a controlled drug
- Manufacturer:
- Incyte Corporation
- National Drug Code (NDC):
- 50881-0005
- Inactive Ingredients:
- microcrystalline cellulose
lactose monohydrate
silicon dioxide
hydroxypropyl cellulose
povidone
sodium starch glycolate type A potato
magnesium stearate
More about Jakafi (ruxolitinib)
Consumer resources
Professional resources
Related treatment guides
Disclaimer:
Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Copyright 2016 Drugs.com, National Library of Medicine, Truven Health Analytics and Cerner Multum, Inc. All Rights Reserved.
